The Chicago Entrepreneur

Gilead’s twice-yearly shot cut HIV infections by 96% in trial

The data sets the stage for likely approval of Gilead’s Lenacapavir for HIV prevention.

Previous post Coinbase’s wrapped Bitcoin token cbBTC goes live
Next post SpaceX performs historic first spacewalk with Polaris Dawn crew